Document is current
Any future updates will be listed below
-
Authors
Zhao, Dan https://orcid.org/0000-0001-7066-9058
Klempner, Samuel J. https://orcid.org/0000-0002-4062-0808
Chao, Joseph https://orcid.org/0000-0002-1809-504X
- License Information
-
More Information
Article History
Received: 14 March 2019
Accepted: 25 April 2019
First Online: 17 May 2019
Ethics approval and consent to participate
: Not applicable.
: Not applicable.
: SJK has received consulting/advisory fees from Eli Lilly, Astellas, Foundation Medicine, Inc., and Boston Biomedical and speaker fees from Merck and Foundation Medicine, Inc. SJK holds stock/equity in TP Therapeutics. JC has received research support (institutional), consulting, and speaker fees from Merck and consulting fees from Lilly Oncology, Taiho, and Daiichi-Sankyo. DZ declares that she has no competing interests.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
